Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
JOURNALS
PSYCHOPHARMACOLOGY BULLETIN
FULL ISSUE STACKED PDFs
T.E.N.
MENTAL FITNESS
PSI
ONCOLOGY SPECTRUMS
PROJECTS
JOURNAL SUPPLEMENTS
PHYSICIAN ACADEMY SERIES
POCKET REFERENCE GUIDES
TEACHING MONOGRAPHS
MEDWORKS REPRINT SERIES
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOTROPIC PRESCRIBING INFORMATION
PSYCHOTROPIC DOSAGE RANGES
PSYCHOPHARMACOLOGY 101
PSYCHIATRIC RATING SCALES
NEWS
WE KNOW PSYCHIATRY
FEATURED ARTICLES
Home
schizophrenia
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
$
0.00
Add to cart
Details
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder
$
0.00
Add to cart
Details
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder
$
0.00
Add to cart
Details
Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder
$
0.00
Add to cart
Details
Psychopharmacology Bulletin VOL 47 No. 2, 2017 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety
$
30.00
Add to cart
Details
Sex Differences in Antipsychotic Related Metabolic Functioning in Schizophrenia Spectrum Disorders
$
30.00
Add to cart
Details
Takefumi Suzuki, MD, PhD: A Potentially Aborted Neuroleptic Malignant Syndrome Following Seclusion Against Uncontrollable Water Intoxication
$
30.00
Add to cart
Details
Nienke Dekker, MD: Cessation of Cannabis Use by Patients with Recent-Onset Schizophrenia and Related Disorders
$
30.00
Add to cart
Details
Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia
$
30.00
Add to cart
Details
A Failed 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of Once-Daily Extended Release Quetiapine Fumarate in Patients with Acute Schizophrenia: Lessons Learned
$
30.00
Add to cart
Details
Lori Davis, MD: Clinical and Pharmacoeconomic Evaluation of Switch to Olanzapine in Veterans with Schizophrenia or Schizoaffective Disorder
$
30.00
Add to cart
Details
Effectiveness of Clozapine use in Delaying Hospitalization in Routine Clinical Practice: A 2 year Observational Study
$
30.00
Add to cart
Details
Financial Incentives to Improve Adherence to Medication in Five Patients with Schizophrenia in The Netherlands
$
30.00
Add to cart
Details
Signal Detection and Placebo Response in Schizophrenia: Parallels with Depression
$
30.00
Add to cart
Details
Todd Lencz, PhD: Neurodevelopmental Models of Schizophrenia: Pathophysiologic Synthesis and Directions for Intervention Research
$
30.00
Add to cart
Details
Joyce E. Myers, MD: Risperidone: Review of Its Therapeutic Utility in Depression
$
30.00
Add to cart
Details
E. Chris Muly, MD, PhD: Signal Transduction Abnormalities in Schizophrenia: the cAMP System
$
30.00
Add to cart
Details
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
$
30.00
Add to cart
Details
Gregor E. Berger, MD, FMH Psych (CH): Incipient Neurovulnerability and Neuroprotection in Early Psychosis
$
30.00
Add to cart
Details
Previous
1
2
3
4
Next
Page load link
Go to Top
